These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 10945623

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R.
    Clin Cancer Res; 2006 Mar 15; 12(6):1839-49. PubMed ID: 16551869
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
    Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, Hallahan DE.
    Cancer Res; 2001 Mar 15; 61(6):2413-9. PubMed ID: 11289107
    [Abstract] [Full Text] [Related]

  • 24. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S, Laird D, Cherrington JM, Knox SJ.
    Radiat Res; 2002 Jan 15; 157(1):45-51. PubMed ID: 11754641
    [Abstract] [Full Text] [Related]

  • 25. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, Glanzmann C, Bodis S, Pruschy M.
    Br J Cancer; 2001 Dec 14; 85(12):2010-6. PubMed ID: 11747347
    [Abstract] [Full Text] [Related]

  • 26. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA, Robinson C, Angeles T, Wilkinson J, Clapper ML.
    Clin Cancer Res; 2002 Jan 14; 8(1):267-74. PubMed ID: 11801568
    [Abstract] [Full Text] [Related]

  • 27. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
    Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R.
    Cancer Res; 2006 Sep 01; 66(17):8715-21. PubMed ID: 16951187
    [Abstract] [Full Text] [Related]

  • 28. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B.
    Cancer Chemother Pharmacol; 2005 Dec 01; 56(6):569-77. PubMed ID: 16001166
    [Abstract] [Full Text] [Related]

  • 29. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD, Sercel AD, Leja BM, Wolfangel CD, Ambroso LA, Elliott WL, Fry DW, Kraker AJ, Howard CT, Lu GH, Moore CW, Nelson JM, Roberts BJ, Vincent PW, Denny WA, Thompson AM.
    J Med Chem; 1997 Feb 14; 40(4):413-26. PubMed ID: 9046331
    [Abstract] [Full Text] [Related]

  • 30. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM.
    J Med Chem; 1998 Aug 13; 41(17):3276-92. PubMed ID: 9703473
    [Abstract] [Full Text] [Related]

  • 31. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
    Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS.
    J Med Chem; 2005 Jun 16; 48(12):3991-4008. PubMed ID: 15943473
    [Abstract] [Full Text] [Related]

  • 32. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
    Farhadi MR, Capelle HH, Erber R, Ullrich A, Vajkoczy P.
    J Neurosurg; 2005 Feb 16; 102(2):363-70. PubMed ID: 15739567
    [Abstract] [Full Text] [Related]

  • 33. SU6668, a multitargeted angiogenesis inhibitor.
    Hoekman K.
    Cancer J; 2001 Feb 16; 7 Suppl 3():S134-8. PubMed ID: 11779084
    [Abstract] [Full Text] [Related]

  • 34. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.
    Cancer Res; 2004 May 15; 64(10):3586-92. PubMed ID: 15150116
    [Abstract] [Full Text] [Related]

  • 35. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE.
    Cancer Res; 2002 Apr 01; 62(7):2034-42. PubMed ID: 11929822
    [Abstract] [Full Text] [Related]

  • 36. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.
    Clin Cancer Res; 2008 Nov 15; 14(22):7272-83. PubMed ID: 19010843
    [Abstract] [Full Text] [Related]

  • 37. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T.
    Cancer Res; 2000 Dec 01; 60(23):6737-43. PubMed ID: 11118060
    [Abstract] [Full Text] [Related]

  • 38. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
    Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM.
    Anticancer Drug Des; 2000 Feb 01; 15(1):29-41. PubMed ID: 10888034
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.
    Cancer Res; 2009 Oct 15; 69(20):8009-16. PubMed ID: 19808973
    [Abstract] [Full Text] [Related]

  • 40. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.
    Angelov L, Salhia B, Roncari L, McMahon G, Guha A.
    Cancer Res; 1999 Nov 01; 59(21):5536-41. PubMed ID: 10554031
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.